Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Net Income: 2020-2025

Historic Net Income for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $215.7 million.

  • Apellis Pharmaceuticals' Net Income rose 475.46% to $215.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.0 million, marking a year-over-year increase of 117.98%. This contributed to the annual value of -$197.9 million for FY2024, which is 62.57% up from last year.
  • As of Q3 2025, Apellis Pharmaceuticals' Net Income stood at $215.7 million, which was up 611.35% from -$42.2 million recorded in Q2 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Net Income peaked at $215.7 million during Q3 2025, and registered a low of -$219.2 million during Q2 2021.
  • Moreover, its 3-year median value for Net Income was -$66.5 million (2024), whereas its average is -$58.7 million.
  • Per our database at Business Quant, Apellis Pharmaceuticals' Net Income slumped by 222.56% in 2021 and then surged by 475.46% in 2025.
  • Quarterly analysis of 5 years shows Apellis Pharmaceuticals' Net Income stood at -$147.9 million in 2021, then decreased by 12.21% to -$166.0 million in 2022, then surged by 46.64% to -$88.6 million in 2023, then spiked by 58.99% to -$36.3 million in 2024, then spiked by 475.46% to $215.7 million in 2025.
  • Its Net Income stands at $215.7 million for Q3 2025, versus -$42.2 million for Q2 2025 and -$92.2 million for Q1 2025.